Drug Synthesis and Evaluation Center
Date：2020-10-30
The primary mission of Drug Synthesis and Evaluation Center is innovation-driven research and development for small molecule drugs and healthcare products. Our center is equipped with integrated platforms for structural design, de novo synthesis, high-throughput bioactivity screening, SAR analysis, pre-clinical pharmacological and pharmacokinetic evaluations, etc. Meanwhile, we also provide customized services for organic synthesis, drug quality/efficacy evaluation and Post-marketed medicine re-evaluations, which help our collaborators improve scientific competitiveness.
Our group members have made collective achievements in medicinal chemistry, pharmacology and Traditional Chinese Medicine (TCM) research. As core members, our staffs have participated in the pre-clinical investigation & evaluation of a Category 1 chemical drug, Phase clinical trial and patent transformation of a Category 5 TCM. We’ve also completed quality and efficacy re-evaluation of several TCMs up to now.
科研方向
新药研发，中药上市后再评价
科研团队组成
中心主任（一级PI）：姚宏亮，药物合成与评价研究中心负责人。主持负责国家级、省部级等项目12项；已发表论文56篇（SCI 41篇）；获授权国家发明专利9件。获得广东医学科技奖、中华中医药学会科技奖、中国产学研合作创新成果奖等5项。
二级PI:暂无
科研成果概况
团队成员目前已在Nat. Commun.、Cancer Res.、Eur. J. Med. Chem.、Hepatology、Oncoimmunology等期刊发表相关SCI论文超过76篇，其中以第一作者/通讯作者发表SCI论文超过35篇。授权国家发明专利9件，另外申请国家发明专利13件、国际PCT专利1件。获得2019年度广东医学科技奖一等奖1项，获得2018年度中华中医药学会科学技术二等奖1项，获得2019年度中华中医药学会科学技术三等奖1项，获得2019年度中国产学研合作创新成果奖二等奖1项，获得2019年度教学成果奖二等奖1项。
团队照片